|
1. Cucinotta D, Vanelli M. WHO Declares COVID-19 a Pandemic. Acta Biomed 2020; 91: 157-60. 2. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia N Engl J Med 2020;382:1199-207. 3. Ren LL, Wang YM, Wu ZQ, Xiang ZC, Guo L, Xu T, et al. Identification of a novel coronavirus causing severe pneumonia in human: a descriptive study. Chin Med J (Engl) 2020;133:1015-24. [ DOI:10.1097/CM9.0000000000000722] 4. Lu CW, Liu XF, Jia ZF. 2019-nCoV transmission through the ocular surface must not be ignored. Lancet 2020;395:e39. [ DOI:10.1016/S0140-6736(20)30313-5] 5. Kubin CJ, McConville TH, Dietz D, Zucker J, May M, Nelson B, et al. Characterization of Bacterial and Fungal Infections in Hospitalized Patients With Coronavirus Disease 2019 and Factors Associated With Health Care-Associated Infections. Open Forum Infect Dis 2021;8:ofab201. [ DOI:10.1093/ofid/ofab201] 6. Song G, Liang G, Liu W. Fungal Co-infections Associated with Global COVID-19 Pandemic: A Clinical and Diagnostic Perspective from China. Mycopathologia 2020 ;185:599-606. [ DOI:10.1007/s11046-020-00462-9] 7. Hibbett DS, Binder M, Bischoff JF, Blackwell M, Cannon PF, Eriksson OE, et al. A higher-level phylogenetic classification of the Fungi. Mycol Res 2007;111:509-47. [ DOI:10.1016/j.mycres.2007.03.004] 8. Spellberg B, Edwards J Jr, Ibrahim A. Novel perspectives on mucormycosis: pathophysiology, presentation, and management. Clin Microbiol Rev 2005;18:556-69. [ DOI:10.1128/CMR.18.3.556-569.2005] 9. Prakash H, Chakrabarti A. Epidemiology of Mucormycosis in India. Microorganisms 2021;9:523. [ DOI:10.3390/microorganisms9030523] 10. Tedder M, Spratt JA, Anstadt MP, Hegde SS, Tedder SD, Lowe JE. Pulmonary mucormycosis: results of medical and surgical therapy. Ann Thorac Surg 1994;57:1044-50. [ DOI:10.1016/0003-4975(94)90243-7] 11. Torres-Narbona M, Guinea J, Martínez-Alarcón J, Muñoz P, Gadea I, Bouza E. MYCOMED Zygomycosis Study Group. Impact of zygomycosis on microbiology workload: a survey study in Spain. J Clin Microbiol 2007;45:2051-3. [ DOI:10.1128/JCM.02473-06] 12. Singh A K, Singh R, Joshi SR, Misra A. Mucormycosis in COVID-19: a systematic review of cases reported worldwide and in India. Diabetes Metab Syndr 2021;15:102146. [ DOI:10.1016/j.dsx.2021.05.019] 13. Veisi A, Bagheri A, Eshaghi M, Rikhtehgar MH, Rezaei Kanavi M, Farjad R. Rhino-orbital mucormycosis during steroid therapy in COVID-19 patients: A case report. Eur J Ophthalmol 2022;32:NP11-16. [ DOI:10.1177/11206721211009450] 14. Saldanha M, Reddy R, Vincent MJ. Title of the Article: Paranasal Mucormycosis in COVID-19 Patient. Indian J Otolaryngol Head Neck Surg 2021:1-4. [ DOI:10.1007/s12070-021-02574-0] 15. Werthman-Ehrenreich A. Mucormycosis with orbital compartment syndrome in a patient with COVID-19. Am J Emerg Med 2021;42:264.e5-264.e8. [ DOI:10.1016/j.ajem.2020.09.032] 16. Sugar AM. Mucormycosis. Clin Infect Dis 1992;14:S126-29. [ DOI:10.1093/clinids/14.Supplement_1.S126] 17. Prakash H, Ghosh AK, Rudramurthy SM, Singh P, Xess I, Savio J, et al. A prospective multicenter study on mucormycosis in India: Epidemiology, diagnosis, and treatment. Med Mycol 2019;57:395-402. [ DOI:10.1093/mmy/myy060] 18. Patel A, Kaur H, Xess I, Michael JS, Savio J, Rudramurthy S, et al. A multicentre observational study on the epidemiology, risk factors, management and outcomes of mucormycosis in India. Clin Microbiol Infect 2020;26:944.e9-944.e15. [ DOI:10.1016/j.cmi.2019.11.021] |
